RxDoctor Payments Data

Shuman Hua, MD

Internal Medicine · Williamsville, NYNPI 1245219229

Payments from drug & device makers

$8,907in general payments, 2019–2025

Across 501 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • AstraZeneca$1K
  • Merck$762
  • Boehringer Ingelheim$746
  • Novo Nordisk$687
  • Amgen$650
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$8,907100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,907 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$92,059
Medicare patients
242
Services billed
3,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$106,603
JardianceEmpagliflozin44$58,607
MounjaroTirzepatide26$41,746
FarxigaDapagliflozin Propanediol11$15,066
OzempicSemaglutide12$14,779
Breo ElliptaFluticasone/Vilanterol18$14,749
Rosuvastatin Calcium437$8,186
Spiriva RespimatTiotropium Bromide14$8,142
Levothyroxine Sodium264$5,413
Metoprolol Succinate242$4,823
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,801
Atorvastatin Calcium301$4,639
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$4,384
SynthroidLevothyroxine Sodium57$3,826
Irbesartan73$2,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$557$106,60390 claims
Boehringer IngelheimJardiance, Spiriva Respimat$746$66,74958 claims
Lilly USA, LLCMounjaro$1,523$41,74626 claims
AstraZenecaFarxiga$1,242$15,06611 claims
Novo NordiskOzempic$687$14,77912 claims
GSKBreo Ellipta$217$14,74918 claims
AbbVieSynthroid$177$3,82657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →